Puechal X, et al. - During this single-centre cohort study, authors gauged efficacy and safety of rituximab (RTX) induction and maintenance therapy for granulomatosis with polyangiitis (GPA). Eligible candidates included all patients with active GPA, not enrolled in trials, who received ≥1 RTX infusion(s) for induction. Data disclosed that the 2-year relapse-free survival and RTX retention rates were 85 and 78% and serious infection and serious adverse event rates were 4.9 and 8.1 per 100 patient-years, respectively. The inference drawn was that RTX induction and low-dose preemptive maintenance could effectively and safely induce sustained remission in GPA in a real-life setting.